Istradefylline prevents central nervous system oxygen toxicity
4 affiliations
- 1PLA Naval Medical Center, Naval Medical University, Shanghai, China
- 2Department of Military and Special Medicine, No. 971th Hospital of PLA Navy, Qingdao, China
- 3Qingdao Medical College, Qingdao University, Qingdao, China
- 4Department of Hyperbaric Oxygen Therapy, Shanghai Changhai Hospital, Shanghai, China
Abstract
Central nervous system oxygen toxicity (CNS-OT) is a toxic reaction induced by inhalation of gases with excessively high partial pressure of oxygen, for which effective proactive preventive and therapeutic measures are currently lacking. Building on our previous work implicating adenosine A2A receptor (A2AR) signaling, we examined the prophylactic effects of istradefylline (KW-6002), an approved A2AR antagonist, in male mice. We found that pretreatment oral administration of istradefylline (0.5–20 mg/kg) in mice significantly prolonged the latency to seizure onset and markedly reduced both the intensity and frequency of seizures during a 30-min exposure to 100% oxygen at 5 ATA. Cortical targeted metabolomics showed that HBO exposure decreased GABA and increased glutamate; istradefylline increased cortical GABA without significantly reducing cortical glutamate. Separate ELISA measurements showed lower hippocampal glutamate in istradefylline-treated mice than in HBO-exposed vehicle controls, whereas reductions in the other regions examined were not statistically significant. In the striatum, istradefylline was associated with lower cAMP, immunoreactive PKA protein concentration, and phosphorylated CREB, together with reduced GluA1 Ser845 phosphorylation and increased GABA_A receptor β3 Ser408/409 phosphorylation. In the cortex, malondialdehyde levels decreased and catalase activity increased, whereas glutathione peroxidase activity decreased further. Striatal IL-1β, IL-6, and TNF-α mRNA levels were also reduced. These findings support a prophylactic effect of istradefylline against HBO-induced seizures in male mice and identify associated changes in neurotransmitter levels, receptor phosphorylation, signaling markers, oxidative-stress measures, and inflammatory-gene expression. These results provide a theoretical basis for the development of proactive preventive and therapeutic strategies for CNS-OT with potential clinical application.
Related
- Defining plasma concentration ranges for central nervous system and cardiovascular toxicity of local anesthetics: A systematic review.
- Central nervous system efficacy of third generation vs. first generation EGFR-TKIs in the first line treatment for EGFR-mutated non-small cell lung cancer with central nervous system metastases: a systematic review and meta-analysis of phase 3 randomized controlled trials
- Late-Detected Sinus Venosus Atrial Septal Defect and Subsequent Enteroviral Central Nervous System Infection: A Case Report
- Giant T-Wave Inversions and Apical Thickening in a Patient with Central Nervous System Lymphoma.
- Plasma and Serum Metagenomic Sequencing of Microbial Cell-Free Nucleic Acids for Suspected Central Nervous System Infection: A Systematic Review
BibTeX
@article{du2026istradefylline,
title = {{Istradefylline prevents central nervous system oxygen toxicity}},
author = {Zongkai Du and Zongkai Du and Ruhan Li and Yue Jiang and Yanan Zhang and Chenggang Zheng and Runping Li},
journal = {Frontiers in Molecular Neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnmol.2026.1922859},
url = {https://doi.org/10.3389/fnmol.2026.1922859},
note = {CC BY},
}
RIS
TY - JOUR
TI - Istradefylline prevents central nervous system oxygen toxicity
AU - Zongkai Du
AU - Zongkai Du
AU - Ruhan Li
AU - Yue Jiang
AU - Yanan Zhang
AU - Chenggang Zheng
AU - Runping Li
PY - 2026
DA - 2026/10/23
JO - Frontiers in Molecular Neuroscience
DO - 10.3389/fnmol.2026.1922859
UR - https://doi.org/10.3389/fnmol.2026.1922859
AB - Central nervous system oxygen toxicity (CNS-OT) is a toxic reaction induced by inhalation of gases with excessively high partial pressure of oxygen, for which effective proactive preventive and therapeutic measures are currently lacking. Building on our previous work implicating adenosine A2A receptor (A2AR) signaling, we examined the prophylactic effects of istradefylline (KW-6002), an approved A2AR antagonist, in male mice. We found that pretreatment oral administration of istradefylline (0.5–20 mg/kg) in mice significantly prolonged the latency to seizure onset and markedly reduced both the intensity and frequency of seizures during a 30-min exposure to 100% oxygen at 5 ATA. Cortical targeted metabolomics showed that HBO exposure decreased GABA and increased glutamate; istradefylline increased cortical GABA without significantly reducing cortical glutamate. Separate ELISA measurements showed lower hippocampal glutamate in istradefylline-treated mice than in HBO-exposed vehicle controls, whereas reductions in the other regions examined were not statistically significant. In the striatum, istradefylline was associated with lower cAMP, immunoreactive PKA protein concentration, and phosphorylated CREB, together with reduced GluA1 Ser845 phosphorylation and increased GABA_A receptor β3 Ser408/409 phosphorylation. In the cortex, malondialdehyde levels decreased and catalase activity increased, whereas glutathione peroxidase activity decreased further. Striatal IL-1β, IL-6, and TNF-α mRNA levels were also reduced. These findings support a prophylactic effect of istradefylline against HBO-induced seizures in male mice and identify associated changes in neurotransmitter levels, receptor phosphorylation, signaling markers, oxidative-stress measures, and inflammatory-gene expression. These results provide a theoretical basis for the development of proactive preventive and therapeutic strategies for CNS-OT with potential clinical application.
SN - 1662-5099
ER -